Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
|
| Abstract |
Skeletal complications caused by osteoporosis or bone metastases are associated with considerable pain, increased mortality, and reduced quality of life. Furthermore, such events place a burden on health care resources. Agents that prevent bone resorption, such as bisphosphonates or denosumab, can reduce the risk of skeletal-related events and are widely used in patients with osteoporosis or bone metastases of cancer. Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but potentially serious, adverse event associated with high cumulative doses of bisphosphonates or denosumab. However, MRONJ can be treated, and the likelihood of the development of this condition can be reduced through prophylactic dental care and the maintenance of good oral hygiene. Dentists, as part of a multiprofessional team, have a critical role in preventing MRONJ. This review describes the incidence and pathophysiology of MRONJ and provides guidance for dental practitioners with regard to the screening, prophylactic treatment, diagnosis, and management of patients with this condition.
|
|---|---|
| Authors | Ourania Nicolatou-Galitis, Morten Schiødt, Rui Amaral Mendes, Carla Ripamonti, Sally Hope, Lawrence Drudge-Coates, Daniela Niepel, Tim Van den Wyngaert |
| Journal | Oral surgery, oral medicine, oral pathology and oral radiology (Oral Surg Oral Med Oral Pathol Oral Radiol) Vol. 127 Issue 2 Pg. 117-135 (Feb 2019) ISSN: 2212-4411 [Electronic] United States |
| PMID | 30393090 (Publication Type: Journal Article, Review) |
| Copyright | Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!